---
title: "Rapamycin (Sirolimus) Legal & Patent Challenges, FDA Label"
description: "A comprehensive clinical and regulatory guide to sirolimus (rapamycin): FDA approval history, patent litigation, current label requirements, and post-market…"
url: https://healthrx.com/regulatory-rapamycin/legal-challenges
publisher: HealthRX.com
---


HealthRX.com

Rapamycin has no approved longevity use under its FDA label

[Print or save as PDF](https://healthrx.com/printables/regulatory-rapamycin/legal-challenges?print=1)

Key numbers

- 6 mg Loading dose on day 1 of the labeled kidney transplant regimen, given with cyclosporine and corticosteroids Source: [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3275b824-3f82-4151-2ab2-0036a9ba0acc), as cited Nov 7, 2026
- 22% Graft loss and excess mortality rate with Rapamune plus tacrolimus in a liver transplant study Source: [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3275b824-3f82-4151-2ab2-0036a9ba0acc), as cited Nov 7, 2026
- 1 mg Daily dose given to adults aged 70 to 95 in an earlier placebo-controlled pilot of rapamycin Source: [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29408453/), as cited Nov 7, 2026

[See the public record for Sirolimus](https://healthrx.com/data/sirolimus)

HealthRX.com quick answer. Sirolimus (Rapamune) is FDA-approved for two uses only: preventing rejection of a transplanted kidney in people aged 13 and older, and treating lymphangioleiomyomatosis (LAM) [1]. Longevity is not an approved use, so using rapamycin for it is off-label [1]. Generic sirolimus tablets and oral solution are approved [1].

At a glance

- Approval record / NDA 021083, original FDA action 09/15/1999 [3]
- Second application / NDA 021110, approved 08/25/2000 [1]
- Approved uses / Kidney transplant rejection prophylaxis (13 and older) and LAM [1]
- Longevity use / Off-label; not an approved indication [1]
- Boxed warning / Immunosuppression; use not recommended in liver or lung transplant [1]
- Metabolism / Substrate of CYP3A4 and P-glycoprotein [1]
- Grapefruit juice / Must not be taken with Rapamune or used to dilute it [1]

## Which labeled indications and doses apply to sirolimus?

Rapamune is an mTOR inhibitor immunosuppressant [1]. Its label lists two indications: prophylaxis of organ rejection in patients aged 13 years and older receiving a kidney transplant, and treatment of lymphangioleiomyomatosis [1]. Labeled transplant dosing is a 6 mg loading dose on day 1 then 2 mg daily with cyclosporine and corticosteroids, or up to 15 mg then 5 mg daily in high-immunologic-risk patients; LAM starts at 2 mg once daily [1].

## Does any label cover rapamycin for aging?

No. No labeled use covers aging, longevity or healthspan [1]. Compounded sirolimus is not FDA-approved, and FDA does not verify the safety, effectiveness or quality of compounded drugs before marketing [2]. The PEARL trial in healthy, normative-aging adults used compounded rapamycin [4].

## What transplant risks does the sirolimus boxed warning give?

The boxed warning is headed Immunosuppression, use is not recommended in liver or lung transplant patients [1]. It covers increased susceptibility to infection and possible lymphoma and other malignancies, particularly of the skin [1]. In a liver transplant study, Rapamune with tacrolimus was associated with excess mortality and graft loss, 22% versus 9% [1]. In de novo lung transplant patients, bronchial anastomotic dehiscence, most fatal, has been reported [1].

## What did PEARL and the older pilot find?

PEARL was a 48-week double-blind, placebo-controlled trial of placebo, 5 mg or 10 mg compounded rapamycin once weekly [4]. Visceral adiposity did not change (p=0.942), adverse and serious adverse events were similar across groups, and the authors said efficacy was not established [4]. An earlier placebo-controlled pilot randomized 25 adults aged 70 to 95 to 1 mg daily or placebo; 11 on rapamycin and 14 on placebo completed at least 8 weeks, and the rapamycin group reported facial rash, stomatitis and gastrointestinal issues [5]. The immune-aging study often cited used everolimus, a different drug, and measured vaccine response rather than longevity [6].

## Patents, generics and compounded copies

Drugs@FDA shows Rapamune under Pfizer with NDA 021083, original action 09/15/1999, and NDA 021110, approved 08/25/2000 [3][1]. Generic sirolimus tablets and oral solution are approved [1]. FDA explains that a generic applicant can challenge a patent listed for a brand product by filing a Paragraph IV certification, and FDA publishes a list of Paragraph IV certifications [7]. Generic sirolimus tablets and oral solution are approved alongside the brand version of [rapamycin](https://healthrx.com/products/rapamycin).

State boards of pharmacy hold primary day-to-day oversight of state-licensed pharmacies that are not registered as outsourcing facilities, while outsourcing facilities are inspected by FDA on a risk-based schedule [2].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. According to the article, which of these is an approved use of Rapamune?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Printable question sheet

Rapamune sirolimus questions for your prescriber or pharmacist

Use this sheet before or at a visit about sirolimus (Rapamune) or generic sirolimus. Fill in why it was prescribed, where your supply comes from, and what to ask about approved uses, off-label use, boxed warning and compounded copies.

[Open the fill-in sheet](https://healthrx.com/printables/regulatory-rapamycin/legal-challenges) Fill it in, print it or save it as a PDF. No sign-up.

Questions worth asking

Choose the questions you want to keep Is the rapamycin I am being offered for longevity approved by the FDA? Which uses are listed on the Rapamune label, and does my condition match one of them? Is my sirolimus prescription the brand Rapamune or an approved generic? Is my compounded sirolimus filled by a state-licensed pharmacy or an FDA-registered outsourcing facility? What does the boxed warning about infection and cancer risk mean for my situation? If I use rapamycin off-label, how will you monitor my safety and side effects?

Frequently asked questions

Is rapamycin FDA-approved for anti-aging or longevity?

No. The Rapamune label lists kidney transplant rejection prophylaxis and lymphangioleiomyomatosis only, with no aging, longevity or healthspan use [1]. The 48-week PEARL trial concluded efficacy was not established [4].

What is Rapamune approved to treat?

Prophylaxis of organ rejection in patients aged 13 and older receiving a kidney transplant, used with cyclosporine and corticosteroids, and treatment of lymphangioleiomyomatosis [1].

When was sirolimus approved by FDA?

Drugs@FDA lists an original action date of 09/15/1999 for Rapamune NDA 021083 and an approval date of 08/25/2000 for NDA 021110 [3][1].

Can sirolimus be compounded?

Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before they are marketed [2]. State boards of pharmacy hold primary day-to-day oversight of state-licensed pharmacies that are not registered as outsourcing facilities [2].

References

Show all 7 references Hide references

1. U.S. National Library of Medicine, DailyMed. Rapamune sirolimus tablets and oral solution (Pfizer) prescribing information. [Rapamune sirolimus tablets and oral solution (Pfizer) label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3275b824-3f82-4151-2ab2-0036a9ba0acc)
2. [Compounding and the FDA: Questions and Answers | FDA](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers).
3. [Drugs@FDA: FDA-Approved Drugs](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021083).
4. Moel M, Harinath G, Lee V, Nyquist A, Morgan SL, Isman A, et al. [Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results](https://pubmed.ncbi.nlm.nih.gov/40188830/). Aging (Albany NY). 2025;17(4):908-936.
5. Kraig E, Linehan LA, Liang H, Romo TQ, Liu Q, Wu Y, et al. [A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects](https://pubmed.ncbi.nlm.nih.gov/29408453/). Exp Gerontol. 2018;105:53-69.
6. Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, et al. [mTOR inhibition improves immune function in the elderly](https://pubmed.ncbi.nlm.nih.gov/25540326/). Sci Transl Med. 2014;6(268):268ra179.
7. [Patent Certifications and Suitability Petitions | FDA](https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/patent-certifications-and-suitability-petitions).

Next in this cluster

Related reading

- [sirolimus Rapamycin compounding](https://healthrx.com/regulatory-rapamycin/compounding-status)
- [sirolimus Rapamycin label updates](https://healthrx.com/regulatory-rapamycin/label-updates)
- [sirolimus Rapamycin regulatory status](https://healthrx.com/rapamycin/regulatory-status-global)
- [sirolimus Rapamycin safety signals](https://healthrx.com/rapamycin/safety-signals-fda)
- [sirolimus Rapamycin (Sirolimus) Pipeline and Next-Gen mTOR Inhibitors](https://healthrx.com/regulatory-rapamycin/pipeline-and-future)
- [sirolimus Rapamycin FAERS](https://healthrx.com/regulatory-rapamycin/safety-signals-faers)
- [sirolimus Rapamycin cost](https://healthrx.com/reviews-rapamycin/cost-reports)
- [sirolimus Rapamycin reviews](https://healthrx.com/reviews-rapamycin/efficacy-reports)
- [sirolimus Rapamycin first 3 months](https://healthrx.com/reviews-rapamycin/first-3-months)
- [sirolimus Rapamycin regret](https://healthrx.com/reviews-rapamycin/regret-and-restart)
- [sirolimus Rapamycin reviews](https://healthrx.com/reviews-rapamycin/satisfaction-trends)
- [sirolimus Rapamycin side effects](https://healthrx.com/reviews-rapamycin/side-effect-reports)
- [sirolimus Rapamycin (Sirolimus) Geriatric (65+) Caregiver Administration Guidance](https://healthrx.com/age-v2-rapamycin/geriatric--caregiver-administration)
- [sirolimus Rapamycin sirolimus opioid interaction](https://healthrx.com/interactions-rapamycin/with-opioids)

![rapamycin legal challenges: lawyers walking up courthouse steps for patent and regulatory case](https://zwulxpn434zaufgz.public.blob.vercel-storage.com/page-images/regulatory-rapamycin/legal-challenges.webp)

Patent litigation and regulatory disputes have shaped how sirolimus reached the market and how its label is enforced. Full rapamycin legal challenges guide and sources at [healthrx.com/regulatory-rapamycin](https://healthrx.com/regulatory-rapamycin).

> Compounded drugs are not FDA-approved or reviewed by FDA for safety, effectiveness, or quality before marketing.
